162 results on '"Henricson, Erik"'
Search Results
2. Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
3. Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales Administered to Patients With Duchenne Muscular Dystrophy
4. Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis
5. Disease Progression Stages and Burden in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Supplemented by Electronic Medical Records
6. Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging
7. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
8. Health related quality of life in young, steroid-naïve boys with Duchenne muscular dystrophy
9. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study
10. Gait Event Detection and Travel Distance Using Waist-Worn Accelerometers across a Range of Speeds: Automated Approach.
11. Gait Characterization in Duchenne Muscular Dystrophy (DMD) Using a Single-Sensor Accelerometer: Classical Machine Learning and Deep Learning Approaches.
12. Findings from the Longitudinal CINRG Becker Natural History Study.
13. Automated Detection of Gait Events and Travel Distance Using Waist-worn Accelerometers Across a Typical Range of Walking and Running Speeds
14. Walk4Me: Telehealth Community Mobility Assessment, An Automated System for Early Diagnosis and Disease Progression
15. Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy(1)
16. Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
17. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
18. Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy1.
19. Randomized Controlled Trial Comparing Acupuncture With Placebo Acupuncture for the Treatment of Carpal Tunnel Syndrome
20. 269th ENMC international workshop: 10 years of clinical trials in Duchenne muscular dystrophy – What have we learned? 9–11 December 2022, Hoofddorp, The Netherlands
21. Genetic modifiers of ambulation in the cooperative international Neuromuscular research group Duchenne natural history study
22. Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy.
23. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients
24. Ataluren treatment of patients with nonsense mutation dystrophinopathy
25. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study
26. THE 6-minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study
27. The cooperative international neuromuscular research group duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used
28. The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures
29. Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids.
30. CINRG PILOT TRIAL OF COENZYME Q10 IN STEROID-TREATED DUCHENNE MUSCULAR DYSTROPHY
31. LIQUID FORMULATION OF PENTOXIFYLLINE IS A POORLY TOLERATED TREATMENT FOR DUCHENNE DYSTROPHY
32. THE 6-MINUTE WALK TEST IN DUCHENNE/BECKER MUSCULAR DYSTROPHY: LONGITUDINAL OBSERVATIONS
33. THE 6-MINUTE WALK TEST AS A NEW OUTCOME MEASURE IN DUCHENNE MUSCULAR DYSTROPHY
34. Dystrophinopathy and the brain: A parent project muscular dystrophy (PPMD) meeting report November 11-12, 2021, New York City, NY
35. RELIABLE SURROGATE OUTCOME MEASURES IN MULTICENTER CLINICAL TRIALS OF DUCHENNE MUSCULAR DYSTROPHY
36. The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD.
37. (-)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy.
38. Identification and Analysis of Bacterial Contamination of Ultrasound Transducers and Multiuse Ultrasound Transmission Gel Bottle Tips Before and After the Aseptic Cleansing Technique.
39. Association Study of Exon Variants in the NF-kappa B and TGF beta Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy
40. The CINRG Becker Natural History Study: Baseline characteristics.
41. Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.
42. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study
43. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
44. Pulmonary Endpoints in Duchenne Muscular Dystrophy. A Workshop Summary.
45. Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy.
46. Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.
47. The 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year.
48. Quality-of-Life Measures in Children With Neurological Conditions: Pediatric Neuro-QOL.
49. Percent-Predicted 6-Minute Walk Distance in Duchenne Muscular Dystrophy to Account for Maturational Influences.
50. CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.